Capricor Therapeutics, Inc. Aktie News

Capricor allegedly misled investors about its DMD therapy's FDA approval prospects; an FDA rejection letter citing lack of efficacy data sent shares down.

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.

Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non-ambulatory DMD patients, offering a unique mechanism and favorable safety profile compared to gene therapies like Elevidys. Strong regulatory designations, strategic partnerships, and a robust cas...

Based on prior, preclinical and clinical data, including 2 small randomized trials, I believe there is a high probability that Capricor Therapeutics' phase 3 trial will be positive. Topline results are expected this November. PUL 2.0 (a skeletal muscle endpoint) remains the primary endpoint, with left ventricle ejection fraction being a key secondary endpoint. Regulatory uncertainty remains on ...

Capricor Therapeutics, Inc. - Special Call Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Madison Wynne El-Saadi - B.

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory update for its Biologics License Application (BLA) for Deramiocel, the Company's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). This update f...

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Capricor between October 9, 2024 and July 10, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 35...